Advertisement

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

Sponsored by Brigham and Women's Hospital

Phase Quota
Phase N/A

The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

Study Start Date: January 2007

Estimated Completion Date: March 2017

Specialties: Cardiology: Clinical Pharmacology,Hypertension Internal Medicine: Cardiology,Clinical Pharmacology Nursing: Cardiology,Clinical Pharmacology Pharmacy: Cardiac/Hypertension,Drug Trials Physician Assistant: Cardiology,Clinical Pharmacology

Interventions

  • Drug: Lisinopril, Atenolol

Inclusion criteria

- Male and female hypertensive participants who were previously studied in SCOR
program.

Exclusion criteria

  • Diabetes
  • Taking other medications beside thyroid or estrogen supplements

Study Locations And Contact Information

  • Brigham and Womens Hospital, Boston Massachusetts

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit ClinicalTrialsLocator.com to find out how you can feature this clinical trial.

Advertisement